Evidence map›Paper›PMID 41799513›Full record

ReviewOncology research2026

Clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives.

Tiffany Chen, Grace Kim, Yekta Rahimi, Monisha Kamdar, Eduardo Fernandez-Hernandez, Karrune Woan, Eric L Tam, George Yaghmour

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tiffany ChenCalifornia University of Science and Medicine, Colton, CA 92324, USA.
Grace KimKeck School of Medicine of USC, University of Southern California, Los Angeles, CA 90033, USA.
Yekta RahimiDepartment of Medicine, Keck School of Medicine of USC, Los Angeles, CA 90033, USA.
Monisha KamdarJane Ann Nohl Division of Hematology and Center for the Study of Blood Disease, USC Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
Eduardo Fernandez-HernandezJane Ann Nohl Division of Hematology and Center for the Study of Blood Disease, USC Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
Karrune WoanJane Ann Nohl Division of Hematology and Center for the Study of Blood Disease, USC Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
Eric L TamJane Ann Nohl Division of Hematology and Center for the Study of Blood Disease, USC Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
George YaghmourJane Ann Nohl Division of Hematology and Center for the Study of Blood Disease, USC Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) remains a biologically heterogeneous disease with historically limited targeted therapies and poor outcomes. The development of menin inhibitors represents a promising shift, particularly for patients harboring

Indexed as

Antineoplastic AgentsLeukemia, Myeloid, AcuteProto-Oncogene ProteinsHumansMolecular Targeted TherapyNucleophosminAntineoplastic AgentsMEN1 protein, humanNPM1 protein, humanNucleophosminProto-Oncogene Proteinsacute myeloid leukemia (AML)bleximenibicovamenibleukemiaMeninmenin inhibitorrevumenibziftomenib

Identifiers

PMID41799513
PMCPMC12963663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.